Literature DB >> 10536172

NK binding capacity and lytic activity depend on the expression of ICAM-1 on target bone tumours.

A Meneghetti1, E Mariani, S Santi, M Riccio, L Cattini, S Paoletti, A Facchini.   

Abstract

Osteosarcoma cell lines are differently lysed by natural killer (NK) lymphocytes. A critical step in the lytic process is the recognition and attachment of effector to target cells. To determine binding capacity and lytic activity of NK cells, we investigated the distribution and role of ICAM-1, 2 and 3 on two osteosarcoma cell lines (HOS and Saos-2) in basal conditions and after TNFalpha treatment. Modulation of ICAM-1 after TNFalpha treatment modified the binding capacity of NK cells to osteosarcoma target cells. This modulation process appears to play a critical role in determining the susceptibility of these cells to NK-mediated lysis.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10536172     DOI: 10.3892/ijo.15.5.909

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  6 in total

1.  p53 activates ICAM-1 (CD54) expression in an NF-kappaB-independent manner.

Authors:  Vassilis G Gorgoulis; Panayotis Zacharatos; Athanassios Kotsinas; Dimitris Kletsas; George Mariatos; Vassilis Zoumpourlis; Kevin M Ryan; Christos Kittas; Athanasios G Papavassiliou
Journal:  EMBO J       Date:  2003-04-01       Impact factor: 11.598

2.  IL-17 enhances the susceptibility of U-2 OS osteosarcoma cells to NK cell lysis.

Authors:  M C Honorati; S Neri; L Cattini; A Facchini
Journal:  Clin Exp Immunol       Date:  2003-09       Impact factor: 4.330

Review 3.  Natural Killer Cell Immunotherapy for Osteosarcoma.

Authors:  Brian P Tullius; Buhvana A Setty; Dean A Lee
Journal:  Adv Exp Med Biol       Date:  2020       Impact factor: 2.622

4.  Chemotherapy-resistant osteosarcoma is highly susceptible to IL-15-activated allogeneic and autologous NK cells.

Authors:  Emilie P Buddingh; Marco W Schilham; S Eriaty N Ruslan; Dagmar Berghuis; Karoly Szuhai; Jolien Suurmond; Antonie H M Taminiau; Hans Gelderblom; R Maarten Egeler; Massimo Serra; Pancras C W Hogendoorn; Arjan C Lankester
Journal:  Cancer Immunol Immunother       Date:  2011-01-15       Impact factor: 6.968

Review 5.  Innate Immune Cells: A Potential and Promising Cell Population for Treating Osteosarcoma.

Authors:  Zenan Wang; Zhan Wang; Binghao Li; Shengdong Wang; Tao Chen; Zhaoming Ye
Journal:  Front Immunol       Date:  2019-05-16       Impact factor: 7.561

Review 6.  Prospects for NK Cell Therapy of Sarcoma.

Authors:  Mieszko Lachota; Marianna Vincenti; Magdalena Winiarska; Kjetil Boye; Radosław Zagożdżon; Karl-Johan Malmberg
Journal:  Cancers (Basel)       Date:  2020-12-11       Impact factor: 6.639

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.